Q-omics provides the consensus-scored PARVG profile across patient tissues and cancer cell-line models. PARVG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PARVG is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PARVG protein abundance shows 31,379 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KIRC, and LSCC as cancer lineages where PARVG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARVG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARVG survival associations across molecular data types. PARVG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARVG RNA expression–survival associations across cancer types. High PARVG expression shows unfavorable associations in LGG, but favorable associations in UCEC, SKCM, SCLC, HNSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PARVG RNA expression.
This table summarizes PARVG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PARVG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARVG shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and THCA. The KIRC box plot shows higher PARVG RNA expression in tumor versus normal tissue (log2 FC = +1.980, t-test p < 0.001).
This table shows molecular features associated with PARVG in patient tissues and cancer cell lines. In patient samples, PARVG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARVG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
